INTERSTELLAR - International Study Evaluating Lupus Outcomes after Anifrolumab Real World Use - INTERSTELLAR

Study identifier:D3461R00072

ClinicalTrials.gov identifier:NCT06314282

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

Medical condition

Systemic lupus erythematosus (SLE)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

200

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 22 Oct 2024
Estimated Primary Completion Date: 30 Nov 2026
Estimated Study Completion Date: 30 Nov 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria